Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

Asan Medical Center

Asan Medical Center in Seoul, South Korea is listed as a site for 1,827 registered clinical trials, 521 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 1,827
Ongoing 521

This page covers the site record Asan Medical Center in Seoul, South Korea: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled. The organization of the same name, Asan Medical Center, also sponsors trials.

Get the Asan Medical Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 1,827 trials counted.

  • Phase 1 212 trials
  • Phase 1/2 144 trials
  • Phase 2 330 trials
  • Phase 2/3 29 trials
  • Phase 3 584 trials
  • Phase 4 150 trials
  • Not applicable 167 trials
  • Observational 211 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 521 trials
  • Completed 916 trials
  • Terminated 207 trials
  • Other 183 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 137

1996: 1 trials (Observational 1) 2001: 2 trials (Phase 3 1, Phase 2 1) 2002: 2 trials (Phase 3 2) 2003: 5 trials (Observational 3, Phase 4 1, Phase 3 1) 2004: 7 trials (Observational 1, Phase 4 2, Phase 3 1, Phase 2 3) 2005: 7 trials (Phase 4 2, Phase 3 4, Phase 2 1) 2006: 31 trials (Observational 1, Not applicable 2, Phase 4 10, Phase 3 6, Phase 2 8, Phase 1/2 1, Phase 1 3) 2007: 24 trials (Observational 2, Phase 4 8, Phase 3 7, Phase 2 5, Phase 1/2 2) 2008: 41 trials (Observational 3, Not applicable 3, Phase 4 11, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 4) 2009: 37 trials (Observational 4, Not applicable 3, Phase 4 7, Phase 3 14, Phase 2 4, Phase 1/2 1, Phase 1 4) 2010: 64 trials (Observational 12, Not applicable 8, Phase 4 10, Phase 3 10, Phase 2 13, Phase 1/2 4, Phase 1 7) 2011: 72 trials (Observational 12, Not applicable 6, Phase 4 10, Phase 3 9, Phase 2/3 1, Phase 2 20, Phase 1/2 1, Phase 1 13) 2012: 77 trials (Observational 9, Not applicable 5, Phase 4 10, Phase 3 28, Phase 2 12, Phase 1/2 3, Phase 1 10) 2013: 83 trials (Observational 8, Not applicable 9, Phase 4 6, Phase 3 31, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 15) 2014: 84 trials (Observational 19, Not applicable 10, Phase 4 7, Phase 3 18, Phase 2/3 2, Phase 2 13, Phase 1/2 5, Phase 1 10) 2015: 94 trials (Observational 22, Not applicable 7, Phase 4 6, Phase 3 32, Phase 2 12, Phase 1/2 4, Phase 1 11) 2016: 84 trials (Observational 14, Not applicable 7, Phase 4 7, Phase 3 26, Phase 2/3 2, Phase 2 14, Phase 1/2 5, Phase 1 9) 2017: 112 trials (Observational 13, Not applicable 15, Phase 4 5, Phase 3 41, Phase 2/3 2, Phase 2 14, Phase 1/2 10, Phase 1 12) 2018: 117 trials (Observational 11, Not applicable 8, Phase 4 5, Phase 3 40, Phase 2/3 2, Phase 2 23, Phase 1/2 14, Phase 1 14) 2019: 115 trials (Observational 18, Not applicable 9, Phase 4 5, Phase 3 31, Phase 2/3 4, Phase 2 23, Phase 1/2 16, Phase 1 9) 2020: 126 trials (Observational 14, Not applicable 13, Phase 4 3, Phase 3 36, Phase 2/3 3, Phase 2 27, Phase 1/2 15, Phase 1 15) 2021: 137 trials (Observational 8, Not applicable 10, Phase 4 8, Phase 3 50, Phase 2/3 2, Phase 2 32, Phase 1/2 10, Phase 1 17) 2022: 131 trials (Observational 9, Not applicable 15, Phase 4 11, Phase 3 43, Phase 2/3 1, Phase 2 21, Phase 1/2 16, Phase 1 15) 2023: 108 trials (Observational 14, Not applicable 10, Phase 4 5, Phase 3 36, Phase 2/3 1, Phase 2 20, Phase 1/2 10, Phase 1 12) 2024: 105 trials (Observational 5, Not applicable 5, Phase 4 3, Phase 3 40, Phase 2/3 3, Phase 2 22, Phase 1/2 9, Phase 1 18) 2025: 92 trials (Observational 5, Not applicable 8, Phase 4 5, Phase 3 41, Phase 2/3 2, Phase 2 12, Phase 1/2 10, Phase 1 9)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 68
2025 92
2024 105
2023 108
2022 131
2021 137
2020 126
2019 115
2018 117
2017 112

Showing 10 of 27 years.

Start your 14-day trial Email me all 27 years as a PDF

2026 is partial: trials registered with a 2026 start date so far, not a full year

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Showing 5 of 1,827 trials.

Start your 14-day trial Email me the first 50 trials as a PDF

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Showing 5 of 335 lead sponsors.

Start your 14-day trial Email me the first 50 lead sponsors as a PDF

Conditions studied

The specific conditions of the trials that list this site, most trials first.

Showing 5 of 513 conditions.

Start your 14-day trial Email me the first 50 conditions as a PDF